Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a Healthcare company (Biotechnology) with a market capitalization of $9.9B. The Maz Rating grades it against the other companies in its sector.
Spyre Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $104.00, Spyre Therapeutics, Inc. trades at 109.1x sales and 8.7x book value. Over the last twelve months it generated about $90M of revenue and a net loss of $260M. It runs a gross margin of 50.0%, an operating margin of -276.5% and a net margin of -291.6%. It shows return on equity of -29.8%, return on invested capital of -23.6% and a free cash flow yield of -2.5%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 27.40. Over the past 52 weeks the share price ranged from $23.01 to $110.64, with a beta of 3.23.
Spyre Therapeutics, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 12 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.